Correlation Between Veracyte and ESSA Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Veracyte and ESSA Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Veracyte and ESSA Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Veracyte and ESSA Pharma, you can compare the effects of market volatilities on Veracyte and ESSA Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Veracyte with a short position of ESSA Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Veracyte and ESSA Pharma.

Diversification Opportunities for Veracyte and ESSA Pharma

-0.77
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Veracyte and ESSA is -0.77. Overlapping area represents the amount of risk that can be diversified away by holding Veracyte and ESSA Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ESSA Pharma and Veracyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Veracyte are associated (or correlated) with ESSA Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ESSA Pharma has no effect on the direction of Veracyte i.e., Veracyte and ESSA Pharma go up and down completely randomly.

Pair Corralation between Veracyte and ESSA Pharma

Given the investment horizon of 90 days Veracyte is expected to generate 0.57 times more return on investment than ESSA Pharma. However, Veracyte is 1.75 times less risky than ESSA Pharma. It trades about 0.04 of its potential returns per unit of risk. ESSA Pharma is currently generating about 0.02 per unit of risk. If you would invest  2,913  in Veracyte on September 4, 2024 and sell it today you would earn a total of  1,499  from holding Veracyte or generate 51.46% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Veracyte  vs.  ESSA Pharma

 Performance 
       Timeline  
Veracyte 

Risk-Adjusted Performance

19 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Veracyte are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Veracyte unveiled solid returns over the last few months and may actually be approaching a breakup point.
ESSA Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ESSA Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Veracyte and ESSA Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Veracyte and ESSA Pharma

The main advantage of trading using opposite Veracyte and ESSA Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Veracyte position performs unexpectedly, ESSA Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ESSA Pharma will offset losses from the drop in ESSA Pharma's long position.
The idea behind Veracyte and ESSA Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Other Complementary Tools

Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas